NIH Funds Research in Four Countries to Improve Islet Transplantation


By: dhtest

The National Institutes of Health will fund studies at 11 research centers in the United States, Canada, Sweden and Norway to look into ways to improve outcomes and lessen the side effects from islet cell transplantations in people with type 1 diabetes.

A transplantation takes islets from donor pancreases and infuses them into the liver of a type 1 patient. If the islets successfully lodge in the liver’s small blood vessels, they begin producing insulin—an astounding result given that the autoimmune aspects of type 1 almost invariably destroy the body’s insulin-making capabilities.

However, islet recipients must take drugs that suppress the immune system and keep it from rejecting the transplants. Researchers will use NIH funding to find more effective combinations of anti-rejection drugs that will reduce toxic side effects and increase the likelihood of the islets “taking.”

Another goal is to find ways to generate a much greater supply of islets so that more type 1s can benefit from transplantations.

NIH diabetes clinical studies



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.